Lagis Enterprise Co (6730) Fair Value & Analysis
Healthcare · TW · Market cap 1.3B TWD
Fair value as of: Jun 24, 2026
Analysis
Lagis Enterprise Co (6730) currently trades at 37.50 TWD, while our model-based Fair Value estimate is 24.71 TWD — implying the stock looks roughly 34.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Lagis Enterprise Co., Ltd. engages in the manufacturing, processing, and sale of surgical instruments, equipment, and related medical devices Taiwan and China. Its products include trocars, include optical tip trocar, dilating tip trocar, shielded bladed tip trocar, blunt tip trocar, TRE trocar system, balloon trocar; single port surgery devices, include advanced single port device, single port kit for TAMIS, and advanced single port device for vNOTES; path cap and shield wound reactors; energy bipolar forceps; suction irrigation systems and irrigation pumps; electrosurgery system; endo endoscopic instruments, include scissors and dissectors, graspers, mini laparoscopy grasping device, and laparoscopic electrode; and retrieval specimen bags. The company sells its products under LAGIS brand name. Lagis Enterprise Co., Ltd. was founded in 2004 and is headquartered in Taichung, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Lagis Enterprise Co (6730) undervalued?
What is the fair value of 6730?
What is the quality score of 6730?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.